ACTU Research | Milton Maxwell

ACTU

Actuate Therapeutics, Inc. Common stock

6.96

+0.10+1.46%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

161.77M

P/E (TTM)

20.47

Basic EPS (TTM)

0.34

Dividend Yield

Recent Filings

8-K

11/28/25Nov 28, 2025

8-K

11/21/25Nov 21, 2025

10-Q

11/13/25Nov 13, 2025

8-K

Actuate prices $15M stock offering

9/10/25Sep 10, 2025

Actuate Therapeutics priced its underwritten public offering of 2,142,858 common shares at $7.00 each on September 10, 2025, expecting $15.0 million in gross proceeds before expenses. The deal, led by Lucid Capital Markets, closes September 11, 2025, with a 30-day option for 321,428 more shares. Funds will support working capital and corporate purposes. Directors and executives face lock-up until December 9, 2025. Offering completion hinges on market conditions.

10-Q

Q2 FY2025 results

8/14/25Aug 14, 2025

Actuate Therapeutics narrowed its Q2 operating loss to $6.0M from $5.4M a year earlier, while YTD loss eased to $12.3M versus $13.2M, driven by a 37% drop in R&D spend to $2.8M amid fewer patients in the Phase 2 mPDAC trial, though G&A jumped 202% to $3.2M on stock-based comp and public costs. Cash burn slowed, ending at $6.5M after $6.6M in financing from a $4.6M private placement and $2.1M under the Committed Equity Facility, but liquidity won't last beyond October without more funds. Topline data showed elraglusib plus chemo boosting median OS to 10.1 months from 7.2 months in pancreatic cancer. No capex or FCF disclosed in the 10-Q. Diluted EPS of $(0.30) aligns with 19.6M shares. Competition from larger biotechs could pressure progress.

About

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

CEO

Mr. Daniel M. Schmitt

IPO

8/13/2024

Website

https://actuatetherapeutics.com

Employees

Sector

Healthcare

Industry

Biotechnology